Maravai LifeSciences (MRVI)
(Delayed Data from NSDQ)
$2.70 USD
-0.18 (-6.25%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $2.72 +0.02 (0.74%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth D Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
MRVI 2.70 -0.18(-6.25%)
Will MRVI be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for MRVI based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MRVI
Maravai LifeSciences Holdings, Inc. (MRVI) Reports Q2 Loss, Lags Revenue Estimates
Maravai LifeSciences Holdings, Inc. (MRVI) Reports Q1 Loss, Tops Revenue Estimates
MRVI: What are Zacks experts saying now?
Zacks Private Portfolio Services
Jushi Holdings Inc. (JUSHF) Reports Q1 Loss, Lags Revenue Estimates
MariMed Inc. (MRMD) Reports Q1 Loss, Lags Revenue Estimates
Stryker (SYK) Surpasses Q1 Earnings and Revenue Estimates
Other News for MRVI
Is MRVI building pressure? NR7 shows up after gaining 2.49%
MRVI forms Stochastic Sell Signal on September 18
MRVI forms Upper Bollinger Band Walk on September 16
Is MRVI positioned for a breakout? 180 Bullish Setup shows up after advancing 1.87%
The technical outlook for MRVI is unchanged after it falls 4.3% on September 12